Wattacheril Julia
Center for Liver Disease and Transplantation, Columbia University Irving Medical Center - NY Presbyterian Hospital, 622 West 168th Street, PH 14-105D, New York, NY 10032, USA.
Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. doi: 10.1016/j.gtc.2019.10.002. Epub 2019 Dec 24.
Nonalcoholic fatty liver disease (NAFLD) represents a global public health burden. NAFLD, while strongly associated with the metabolic syndrome, can occur independently from existing metabolic diseases. In addition to liver-related disease burden and mortality, significant extrahepatic disease outcomes coexist with NAFLD, including cardiovascular diseases, chronic kidney disease, and type 2 diabetes. Management of these comorbidities contributes to the overall public health burden of NAFLD. These extrahepatic manifestations require healthcare interventions that are vigilant in monitoring for progression of liver disease while simultaneously managing overall morbidity and mortality from other organ systems.
非酒精性脂肪性肝病（NAFLD）是一项全球性的公共卫生负担。NAFLD虽然与代谢综合征密切相关，但也可能独立于现有的代谢性疾病而发生。除了与肝脏相关的疾病负担和死亡率外，NAFLD还伴有显著的肝外疾病后果，包括心血管疾病、慢性肾脏病和2型糖尿病。对这些合并症的管理加重了NAFLD的总体公共卫生负担。这些肝外表现需要医疗干预，既要密切监测肝脏疾病的进展，同时又要控制其他器官系统的总体发病率和死亡率。
